Serina Therapeutics Launches Enhanced Corporate Communications Platform to Strengthen Engagement with Patients, Clinicians, and Investors

Rhea-AI Summary

Serina Therapeutics (NYSE: SER) launched an enhanced corporate communications platform on October 8, 2025 to deliver timely, transparent updates to patients, clinicians, investors, and the scientific community. The platform will offer regular digital updates, educational resources, multimedia content (including a podcast), expert commentary, webinars, and online forums to support engagement.

Serina said the initiative will coincide with preparations to initiate the planned registrational study of SER-252 in Parkinson’s disease. The SER-252-1b trial is a randomized, double-blind, placebo-controlled Phase 1b with single-ascending-dose (five cohorts of eight; n=40) and multiple-ascending-dose components (up to three cohorts of 16; n=48), conducted in the U.S. and Australia to evaluate safety, tolerability, and pharmacokinetics with exploratory efficacy measures.

Positive

• Launched comprehensive stakeholder communications platform on Oct 8, 2025
• Announced planned registrational SER-252 Phase 1b trial initiation
• Defined trial size: single-asc n=40 and multi-asc up to n=48 (up to n=88 total)
• Planned multi-country trial sites in the U.S. and Australia

Negative

• Study is early-stage Phase 1b with only exploratory efficacy measures
• Trial cohort sizes are limited (up to 88 participants), constraining efficacy conclusions

Insights

Biotech clinical-program analyst

Serina expands stakeholder communications and outlines a Phase 1b registrational design for SER-252 in Parkinson's disease.

Serina Therapeutics centralizes updates via a corporate communications platform to share program, regulatory, and scientific information and will publish regular digital updates, educational material, multimedia content, and engagement events. The company describes the planned SER-252-1b randomized, double-blind, placebo-controlled Phase 1b registrational study with a single-ascending-dose portion (five cohorts of eight; n=40) and multiple-ascending-dose portion (up to three cohorts of sixteen; n=48), measuring safety, tolerability, and pharmacokinetics with exploratory MDS-UPDRS motor and structured motor-state assessments.

The platform improves transparency but does not itself change clinical risk or outcomes; program progress depends on trial initiation, safety reviews by the Safety Review Committee, and regulatory interactions across U.S. and Australian sites. Key risks remain trial safety signals, enrollment pace, and the exploratory nature of efficacy measures; communications can shape perception but not clinical or regulatory results.

Concrete items to watch: initiation and first dosing of the SER-252-1b study, Safety Review Committee decisions during dose escalation, interim safety or PK reports, and any regulatory filings or site activations in the U.S. and Australia. Expect operational updates over the next quarters following the Oct. 08, 2025 announcement as the company moves toward first-in-study dosing.

HUNTSVILLE, AL., Oct. 08, 2025 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. (“Serina”) (NYSE American: SER), a clinical-stage biotechnology company developing its proprietary POZ Platform^™ drug optimization technology, today announced the launch of a comprehensive corporate communications platform designed to deliver timely, transparent updates to patients, clinicians, investors, and the broader scientific community.

The new initiative expands Serina’s direct channels of communication to provide stakeholders with clear, accessible information on the Company’s programs, regulatory progress, and scientific advances. The platform will feature regular digital updates, educational resources, multimedia content, and expert commentary from company leadership and scientific advisors.

“At Serina, we believe leadership in biotechnology requires not only advancing innovative science but also communicating that progress with clarity and transparency,” said Steve Ledger, Chief Executive Officer of Serina Therapeutics. “As we prepare to initiate the planned trial of SER-252 in Parkinson’s disease, this new communications platform will serve as a vital resource for patients, clinicians, investors, and the broader scientific community. By providing timely updates and expert perspectives, we are ensuring that all stakeholders can follow our journey as we work to bring meaningful new treatment options to people living with Parkinson’s disease and other serious conditions.”

As part of the initiative, Serina plans to provide:

• Program and clinical updates delivered through the Company’s website and newsletters.
• Educational resources for physicians, patients, and scientists to better understand the potential of POZ-enabled therapeutics in improving therapeutic performance across multiple modalities.
• Multimedia content, including a new podcast series, to highlight perspectives from company leaders, investigators, and thought leaders in neuroscience and other therapeutic areas.
• Opportunities for engagement, including webinars and online forums to support dialogue with patient and professional communities.

This platform is designed to complement Serina’s ongoing clinical and regulatory activities, providing stakeholders with real-time access to relevant information as the Company advances its pipeline.

SER-252 Registrational Study Design Overview

The SER-252-1b study is a randomized, double-blind, placebo-controlled Phase 1b trial with single-ascending-dose (five cohorts of eight; n=40) and multiple-ascending-dose components (up to three cohorts of sixteen; n=48) in adults with Parkinson’s disease and motor fluctuations. The registrational study is designed to evaluate safety, tolerability, and pharmacokinetics of subcutaneous SER-252 versus placebo, with exploratory efficacy measures that include MDS-UPDRS motor scores and structured motor-state assessments. Dose escalation will be overseen by a Safety Review Committee and the study will be conducted across sites in the U.S. and Australia.

About SER-252 (POZ-apomorphine)

SER 252 is an investigational apomorphine therapy developed with Serina’s POZ platform and designed to provide continuous dopaminergic stimulation (CDS) via a single or twice-weekly subcutaneous injection. CDS has been shown to reduce the severity of motor fluctuations (which includes levodopa-induced dyskinesia) and enable greater daily on time, with reduced off time, in advanced Parkinson’s patients. SER-252 leverages strategic partner Enable Injections’ enFuse^™ wearable drug delivery platform to enhance patient comfort and convenience, providing CDS to patients via an easy-to-administer, long-acting subcutaneous injection.

About Serina Therapeutics

Serina is a clinical-stage biotechnology company developing a pipeline of wholly owned drug product candidates to treat neurological diseases and other indications. Serina’s POZ Platform^™ provides the potential to improve the integrated efficacy and safety profile of multiple modalities including small molecules, RNA-based therapeutics, and antibody-based drug conjugates (ADCs). Serina is headquartered in Huntsville, Alabama on the campus of the HudsonAlpha Institute of Biotechnology. For more information, please visit https://serinatx.com.

For inquiries, please contact:
Stefan Riley
sriley@serinatherapeutics.com
(256) 327-9630

FAQ

What did Serina (SER) announce on October 8, 2025?

Serina announced a new corporate communications platform to provide updates to patients, clinicians, investors, and scientists and described the planned SER-252 Phase 1b study.

What is the design and size of the SER-252-1b registrational study (SER)?

The SER-252-1b study is a randomized, double-blind, placebo-controlled Phase 1b with single-ascending-dose (five cohorts of eight; n=40) and multiple-ascending-dose components (up to three cohorts of 16; n=48).

When and where will Serina (SER) run the SER-252 Phase 1b trial?

Serina said the trial will be conducted across sites in the U.S. and Australia; the company is preparing to initiate the planned study.

How can investors and patients access Serina (SER) updates and resources?

Serina will publish program and clinical updates, educational materials, multimedia content, podcasts, webinars, and forums via its new corporate communications platform and website.

What endpoints will the SER-252 Phase 1b study evaluate for SER?

The study will evaluate safety, tolerability, and pharmacokinetics of subcutaneous SER-252 versus placebo with exploratory efficacy measures including MDS-UPDRS motor scores and structured motor-state assessments.